---
title: Reduce slowness using brain stimulation
nct_id: NCT07397377
phase: NA
status: RECRUITING
sponsor: Danish Research Centre for Magnetic Resonance
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07397377"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07397377"
last_fetched: "2026-05-10T14:07:18.016Z"
source: "Parkinson's Pathways (curated)"
---
# Reduce slowness using brain stimulation

**Goal (in five words):** Reduce slowness using brain stimulation

**Official Title:** Enhancing rTMS Effects Through a State-Dependent Approach - An Intervention for Bradykinesia in Parkinson's Disease

**Trial ID:** [NCT07397377](https://clinicaltrials.gov/study/NCT07397377)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Danish Research Centre for Magnetic Resonance
- **Target Enrollment:** 27 participants
- **Start Date:** 2025-12-16
- **Completion Date:** 2027-05-01
- **Conditions:** Bradykinesia, Parkinson Disease
- **Interventions:** Active patterned repetitive transcranial magnetic stimulation (prTMS), Sham patterned repetitive transcranial magnetic stimulation (prTMS)
- **Intervention Types:** DEVICE

## Summary For Families

The goal is to reduce bradykinesia, the slowness and reduced movement many people with Parkinson's experience, by boosting the effect of brain stimulation. The approach uses patterned repetitive transcranial magnetic stimulation, noninvasive magnetic pulses delivered to motor brain areas and timed to a person’s brain state to strengthen motor circuits, tested against a sham; it is meant to complement usual Parkinson’s medicines, such as levodopa, not replace them. Adults 18 to 80 with clinically established or probable Parkinson’s who have been on stable antiparkinsonian medication for at least four weeks can apply. People with a personal or close family history of epilepsy, certain psychiatric or GABAergic medications, frequent benzodiazepine or opioid use, pregnancy, or MRI/TMS contraindications are excluded.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

Above 18 years of age. Clinically established or probable Parkinson's Disease (PD), according to the Movement Disorder Society.

Clinical Diagnostic Criteria for PD. Stable antiparkinsonian medicine for at least four weeks. Signed informed consent.

Exclusion Criteria:

Psychiatric disorders. Current use of antipsychotic medication, Donepezil, or GABAergic agents (e.g., pregabalin, gabapentin).

Frequent benzodiazepine or opioid use defined as more than once per week on a regular basis.

History of neurological disease other than PD. Past or present mental illness. History of epilepsy/conditions associated with increased risk of seizure induction through transcranial magnetic stimulation (TMS).

Close relatives suffering from epilepsy/conditions associated with increased risk of seizures.

Contraindications for magnetic resonance imaging (MRI) Contraindications for TMS Female participants of childbearing age must not be pregnant and must use contraception during the trial.

Refuse to be informed about new health-related information and accidental health-related findings that might appear through participation in the study.
```

## Locations (1)

- DRCMR, Hvidovre, Denmark _(55.6430, 12.4771)_
  - Hartwig Siebner, Head of Research, Prof., DMSc — (CONTACT) — +45 38 62 65 41 — hartwig@drcmr.dk

## Central Contacts

- Ann-Charlot Rughaven, M.Sc. — (CONTACT) — +4521123531 — ann-charlot.rughaven@regionh.dk

---

*Canonical: https://parkinsonspathways.com/trial/NCT07397377*  
*HTML version: https://parkinsonspathways.com/trial/NCT07397377*  
*Source data: https://clinicaltrials.gov/study/NCT07397377*